The antibodies were tested on sections obtained from AD, progressive supranuclear palsy (PSP) and PiD patients to ascertain if they recognise the pathological tau inclusions characterising these cases. The gene discussed is MAPT; the disease is supranuclear palsy, progressive, 1.